Log In
Print this Print this

PINTA 745 (formerly AMG 745)

  Manage Alerts
Collapse Summary General Information
Company Atara Biotherapeutics Inc.
DescriptionRecombinant Fc-peptide fusion protein
Molecular Target Myostatin (MSTN) (GDF8)
Mechanism of ActionMyostatin (GDF-8) inhibitor
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationEnd-stage renal disease (ESRD)
Indication DetailsTreat patients with end-stage renal disease (ESRD) who are on hemodialysis and have protein energy wasting (PEW)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today